Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?
- 31 December 2011
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 32 (12) , 694-699
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or AnacetrapibArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trialEuropean Heart Journal, 2010
- Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndromeAmerican Heart Journal, 2009
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009
- Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) TrialThe American Journal of Cardiology, 2009
- Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial InfarctionCirculation: Cardiovascular Genetics, 2009
- Torcetrapib‐induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosteroneBritish Journal of Pharmacology, 2008
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Effect of Torcetrapib on the Progression of Coronary AtherosclerosisNew England Journal of Medicine, 2007